Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
Schuler M, Gajate P, Cathomas R, Rajagopalan P, Grevel J, Bender S, Boix O, Nogai H, Ocker M, Ellinghaus P, Schostak M, Park S, Cho B, Sayehli C, Navarro A, Soo R, Richly H, Cassier P, Tai D, Penel N, Nogova L, Jörger M. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol 2019
09.08.2019
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
09.08.2019
Lancet Oncol 2019
Schuler Martin, Gajate Pablo, Cathomas Richard, Rajagopalan Prabhu, Grevel Joachim, Bender Sebastian, Boix Oliver, Nogai Hendrik, Ocker Matthias, Ellinghaus Peter, Schostak Martin, Park Se Hoon, Cho Byoung Chul, Sayehli Cyrus Michael, Navarro Alejandro, Soo Ross A, Richly Heike, Cassier Philippe Alexandre, Tai David, Penel Nicolas, Nogova Lucia, Jörger Markus
Weiter
